Value Based Agreements Uk

The NICE revision may veto a UK price increase for an existing indication, but not a new indication. The second, Patient Access Schemes, involves the company and the DH agreeing to an agreement for the supply of a drug initially refused by NICE – essentially a “quick” check. In the article, Professor Towse investigates how one of the parties might try to “play” the new measures and counters for such attempts. Professor Towse also notes that, since the PPRS agreement, an “Innovation Pass” mechanism managed by NICE has been set up during discussions on the Life Sciences Office. Essentially a form of conditional authorization, which allows early access to a small number of new drugs with limited but very positive evidence of efficacy. .